Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roche's latest targeted medicines, Perjeta and Kadcyla

VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy availability in many non-U.S. countries globally

Dec 13, 2013, 08:00 ET from Ventana Medical Systems, Inc.

$countyNameToPathMap.put("sp